PDE2A and cancer: Conversely, we observed a notable decline in the methylation level of PDE2A in a range of cancer types, including BLCA, BRCA, CHOL, COAD, HNSC, KIRC, LIHC, LUAD, LUSC, READ, SARC, TGCT, and UCEC compared to normal tissues (Figure 5).